Original Research and the Latest News

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

by | October 26, 2025 | Business, Data Analytics, Industry Trends, Market Scan, New Technology, Probability of Success | 0 Comments

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

by | October 16, 2025 | New Technology, Probability of Success | 0 Comments

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

We’re Back!

Oct 27, 2017 |

Ozmosi has been on a purpose-driven hiatus peppered with innovation, development and growth. In less than one year, we have...

Recent Tweets

Ozmosi Follow

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: https://t.co/IBOqbSoYuc Clinical trial tools: https://t.co/A77u9Q84Dc https://t.co/AQERg9nHrb

OzmosiHealth
ozmosihealth Ozmosi @ozmosihealth ·
13h

🚀🚨 BIOPHARM CATALYST ALERT 📆

$ABBV AbbVie will present Phase 1 Multiple Myeloma Data for Etentamig (BCMA Inhibitor,CD3 Inhibitor - Bispecific Antibody) tomorrow 👀

Reply on Twitter 1996900490995814519 Retweet on Twitter 1996900490995814519 Like on Twitter 1996900490995814519 Twitter 1996900490995814519
ozmosihealth Ozmosi @ozmosihealth ·
13h

🚀🚨 BIOPHARM CATALYST ALERT 📆

$BMY Bristol-Myers Squibb will present Phase 2 Multiple Myeloma Data for Iberdomide (CRBN Modulator,IKZF1 Inducer,IKZF3 Inducer - Small Molecule) tomorrow 👀

Reply on Twitter 1996900490337308944 Retweet on Twitter 1996900490337308944 Like on Twitter 1996900490337308944 Twitter 1996900490337308944
ozmosihealth Ozmosi @ozmosihealth ·
13h

🚀🚨 BIOPHARM CATALYST ALERT 📆

$ABBV AbbVie will present Phase 3 Myelodysplastic Syndrome Data for Venetoclax (BCL2 Inhibitor - Small Molecule) tomorrow 👀

Reply on Twitter 1996900491662709072 Retweet on Twitter 1996900491662709072 Like on Twitter 1996900491662709072 Twitter 1996900491662709072
ozmosihealth Ozmosi @ozmosihealth ·
13h

🚀🚨 BIOPHARM CATALYST ALERT 📆

$BMY Bristol-Myers Squibb will present Phase 1 Multiple Myeloma Data for Arlocabtagene autoleucel (CAR-T,GPRC5D - Autologous CAR-T) tomorrow 👀

Reply on Twitter 1996900489582280985 Retweet on Twitter 1996900489582280985 Like on Twitter 1996900489582280985 Twitter 1996900489582280985
Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

Get in Touch

info@ozmosi.com
(732) 701-7807

600 Warren Ave,
Spring Lake, NJ 07762